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Abstract: As the number of persons chronically prescribed antiretrovirals has grown and the 
realization that antiretrovirals are required to be continued for life, pharmaceutical manufacturers 
have developed new classes of agents, improved the pharmacokinetics of marketed products 
through dosing reformulations, and in an effort to maximize success with respect to adher-
ence, compiled into a single dosing unit all necessary elements for an antiretroviral regimen. 
Atripla™ represents the ﬁ  rst ever ﬁ  xed-dose combination antiretroviral available. This article 
reviews currently available data on this agent, the impact of resistance on clinical use and 
implementation, as well as extensive descriptions of the pharmacokinetics, adverse effects and 
drug-interactions warranting consideration. Whether beginning in a naïve patient or switching 
from other regimens for tolerability issues, Atripla™ represents a viable option. Its demonstrated 
advantages with respect to lipid and hematologic parameters and equivalent incidence of renal 
toxicity are tempered by the ﬁ  ndings of bone mineral density decreases, however. Combining 
multiple mechanisms of action in a single dosing unit appears to improve efﬁ  cacy, increase 
the likelihood for adherence and maintain viral suppression compared to administering these 
agents independently. It is suggested other pharmaceutical companies assess the potential to 
replicate this for the remaining antiretrovirals.
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Introduction
Over a decade ago, highly effective antiretroviral therapies became available 
(Abramowicz 2006; Hammer et al 2006; Bartlett and Lane 2007) for persons infected 
with HIV. Correspondingly, the rate of deaths due to AIDS was dramatically reduced 
and the number of persons living with HIV/AIDS has continued to increase (Palella 
et al 1998; Egger et al 2002; CDC 2005). As the number of persons chronically pre-
scribed antiretrovirals has grown and the realization that these would be required to be 
continued for life, pharmaceutical manufacturers have developed new classes of agents, 
improved the pharmacokinetics of marketed products through dosing reformulations 
and in an effort to maximize success with respect to adherence, compiled into a single 
dosing unit all necessary elements for an antiretroviral regimen (Finzi et al 1999; 
Heeswijk et al 2000; Eron et al 2004; Montfore et al 2005; Goedken and Herman 
2005; Moyle et al 2005; Atripla™ 2006; Bartlett et al 2006). Atripla™ (Gilead Sciences, 
Foster City, CA, and Bristol-MyersSquibb, Newark, NJ, USA) is the ﬁ  rst example of 
a ﬁ  xed-dose combination (FDC) containing all elements of a preferred antiretroviral 
regimen as recommended in the most recent HIV treatment guidelines (Atripla™ 
2006; Bartlett and Lane 2007). Atripla™ is a FDC tablet containing three antiretroviral 
medications consisting of the previously US Food and Drug Administration (FDA) 
approved agents: efavirenz (available as Sustiva®, Bristol-MyersSquibb, Newark, 
NJ, USA), emtricitabine (available individually as Emtriva®, Gilead Sciences, or in 
combination with tenofovir diprovoxil fumarate as Truvada®, Gilead Sciences) and Therapeutics and Clinical Risk Management 2008:4(2) 292
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tenofovir diprovoxil fumarate (abbreviated here as tenofovir, 
available individually as Viread®, Gilead Sciences, or in 
combination with emtricitabine as Truvada®) (Young et al 
1995; Robbins et al 1998; Truvada® 2006) This article pro-
vides a concise summary of this product, the implications for 
prescribing this agent initially or switching patients to this 
one tablet once daily regimen who may already be receiving 
effective therapy and an informative primer for those wishing 
to learn more about the virus itself as it pertains to the newest 
approved antiretrovirals.
Review of the microbiology of HIV
The human immunodeﬁ  ciency virus (HIV) is a retrovirus 
that is the causative agent of acquired immunodeﬁ  ciency 
syndrome (AIDS) (Broder and Gallo 1984). Since its initial 
discovery major advancements in therapy have been based 
upon the structure of the virus. Most recently, approval of 
chemokine receptor antagonists and integrase inhibitors 
reinforce the need for clinicians to be familiar with a most 
up-to-date description of the virus’ life cycle (Levy 2007) 
HIV is transmitted by sexual contact, perinatally or by 
blood (most commonly by contaminated shared needles) 
(Tirelli et al 1985). The HIV genome is comprised of the 
structural genes gag and env, which encode the capsid and 
matrix proteins, and the glycoproteins gp120 and gp41 
respectively. HIV gp120 binds to the CD4 receptor on the 
surface of T-lymphocytes, and the cell surface proteins CCR5 
or CXCR4 act as coreceptors for viral attachment (Chan 
and Kim 1998). It is the CCR5 chemokine receptor targeted 
by the FDA-approved drug, maraviroc (Selzentry®, Pﬁ  zer, 
New York, NY, USA) (Bartlett et al 2006) HIV-encoded 
enzymes include a reverse transcriptase (RT), integrase, 
and protease (PR) that are encoded by the pol gene. The 
integrase enzyme is the target for raltegravir – the ﬁ  rst agent 
approved in a new class of antiretrovirals (Markowitz et al 
2006). The remaining HIV genes (tat, rev, vpr, nef, vif, and 
vpu) encode non-structural regulatory proteins that facilitate 
HIV infection and replication and are the targets in ongoing 
drug discovery (Levy 1993; Sarkar et al 2007). It is the viral 
RT enzyme which is the target for the antiretroviral agents 
contained in Atripla™.
Viral replication occurs throughout HIV infection although 
patients are often asymptomatic (Coombs et al 1989; Ho et al 
1989). Treatment with HIV-1 RT inhibitors causes a rapid 
exponential decrease in plasma levels of virus, reﬂ  ecting the 
short half-life of free virus, which has been estimated to be less 
than 6 hours (Wei 1995; Perelson et al 1996). Antiretroviral 
therapy-dependent reduction in viral levels results in HIV 
plasma levels that are often below the detection limit within 
the ﬁ  rst month after initiating (Gulick et al 1997; Hammer 
et al 1997; Markowitz et al 2006; Bartlett et al 2006). In fact, 
due to the high likelihood of this precipitous decline shortly 
after initiating therapy, it is recommended to have patients 
newly started on antiretrovirals to return for a follow-up to 
measure viral load within the ﬁ  rst 4 weeks (Bartlett and 
Lane 2007). HIV-1 replication occurs primarily in activated 
CD4+ T cells, but there is evidence that latent HIV-1 infec-
tion can take place in resting CD4+ T cells (Folks et al 1986; 
Nabel and Baltimore 1987; Chun et al 1995). These infected 
cells form a stable, long-term reservoir of latent virus in the 
form of resting memory CD4+ T cells that carry integrated 
provirus in vivo (Garcia-Blanco and Cullen 1991; Chun et al 
1995, 1997). The latently infected CD4+ T lymphocytes are 
a major barrier for virus eradication and treatment of infec-
tion. The latent virus reservoir is, unfortunately, very stable 
(t ½   43 months) in patients on therapy (Finzi et al 1999). 
Thus, a conservative estimate provides that at minimum of 
60.8 years of treatment would be required to eradicate this 
viral reservoir. Therefore, life-long antiviral therapy for all 
HIV-infected individuals is a necessity.
Atripla™ has two distinct mechanisms for reducing and/
or eliminating replicating virus. This aligns with the most 
recent treatment guidelines approach to effective antiretro-
viral therapy (see Efﬁ  cacy section below) (Bartlett and Lane 
2007). Efavirenz is an HIV-1 speciﬁ  c non-nucleoside reverse 
transcriptase inhibitor (NNRTI) that acts as a noncompeti-
tive inhibitor of HIV RT (Young et al 1995). The in vitro 
susceptibility of efavirenz has been assessed for wild type 
laboratory and clinical strains of HIV in lymphoblastoid cell 
lines, peripheral blood mononuclear cells (PBMCs), and 
macrophage/monocyte cultures and the IC90-95 ranged from 
1.7 to 2.5 nM (Atripla™ 2006). The plasma levels required 
for this and the other two components of Atripla™ to achieve 
and maintain efﬁ  cacy are well surpassed as detailed in the 
pharmacology section below.
A second Atripla™ component is emtricitabine. This 
synthetic nucleoside analog of cytidine has activity against 
HIV-1 RT as a nucleoside RT inhibitor (NRTI). It is 
phosphorylated by cellular enzymes to form emtricitabine 
5’-triphosphate (Frampton and Croom 2006). Activated 
emtricitabine inhibits viral RT by competing with deoxy-
cytidine 5’-triphosphate (a natural substrate), incorporates 
into nascent viral DNA, resulting in chain termination 
and cessation of viral replication. The antiviral activity of 
emtricitabine has been assessed for laboratory and clinical 
isolates of HIV-1 in lymphoblastoid cell lines (MAGI-CCR5) Therapeutics and Clinical Risk Management 2008:4(2) 293
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and PBMCs and antiviral activity was observed against HIV-
1 clades A, B, C, D, E, F, and G (EC50 values ranged from 
0.007 to 0.075 µM) (Atripla™ 2006).
Tenofovir , the third component of Atripla™, is an acyclic 
nucleoside phosphonate diester analog of adenosine mono-
phosphate containing a phosphomimetic group. Tenofovir 
requires initial diester hydrolysis for conversion to tenofovir 
(a NRTI) and subsequent diphosphorylations by cellular 
enzymes to form tenofovir diphosphate (Chapman et al 2003; 
Dando and Wagstaff 2004; Frampton and Croom 2006). 
This is distinct from the other NRTIs in that those require 
triphosphorylation in order to become activated. Tenofovir 
can sometimes found abbreviated as “NtRTI” to distinguish 
it from the nucleoside based agents if not all grouped together 
(Bartlett and Lane 2007). Tenofovir disphosphate is the active 
component that then acts as a competitive inhibitor of the 
natural substrate (dATP. deoxyadenosine 5’-triphosphate). 
Like emtricitabine, tenofovir is incorporated into nascent 
viral DNA and acts as a chain terminator, resulting in the 
cessation of viral replication. The in vitro activity against 
laboratory and clinical HIV isolates has been assessed in 
lymphoblastoid cells lines, primary monocyte/macrophage 
cells and peripheral blood lymphocytes, and the IC50 was 
determined to be 0.04 to 8.5 mM.
Each active component of Atripla™ inhibits the activity 
of HIV RT and results in the inhibition of viral replication 
(Lyseng-Williamson et al 2004; Frampton and Perry 2005) 
and all demonstrate antiviral activity in vitro against clinical 
isolates and laboratory strains of HIV-1 in lymphoblastoid 
cells lines, PBMCs, macrophage/monocyte cell lines (tenofo-
vir and efavirenz only), and MAGI CCR5 cells (emtricitabine 
only) (Young et al 1995; Truvada® 2006; Sustiva® 2007).
Review of resistance to Atripla™
In an infected person, the HIV population is heterogeneous 
and the genome is considered to be in a dynamic state 
(Perelson et al 1996; Charpentier et al 2006). During admin-
istration of antiretroviral drugs, selective pressure is applied 
to the viral genome, and mutations that can lead to or confer 
resistance to the drug(s) present are selected and ampliﬁ  ed 
(Badri et al 2007). As a result, virus replication in the 
presence of antiretroviral continues to result in increases in 
drug resistance in the population. HIV resistance to NNRTIs 
can require as little as one mutation in the HIV RT enzyme 
(Sustiva 2007). As the population of HIV infected persons 
continues to grow and increasing numbers of people are 
prescribed antiretrovirals, the likelihood HIV drug resistance 
becomes a global issue that must be considered as new 
antiretroviral drugs and drug combinations are introduced 
(Little and Smith 2005). An annual guide to interpreting 
drug resistance mutations is provided free-of-charge by the 
International AIDS Society and should be considered as 
invaluable to those caring for HIV-infected persons (Johnson 
et al 2007).
This is perhaps of greatest interest in those persons 
becoming newly infected. Questions arise as to whether or 
not these individuals are having resistant or relatively naïve 
virus transmitted. Recent published trends for resistance, 
using standard assays, a large database (n = 822) and 10 years 
of results, have proposed a stable 7.7% rate of transmission 
of resistant virus to newly infected (Yerly et al 2007). Others, 
albeit smaller cohorts, show HIV being transmitted as resis-
tant virus in 9.1% of newly infected (Wensing et al 2006) Of 
greater concern is the disparity between current reported rates 
of resistance in chronically infected persons using a standard 
versus a new experimental assay. Using an “ultradeep 
sequencing” assay, an increase in the proportion of persons 
with detectable resistance mutations rose from 12% to 20% 
and from 13% to 30% in the International AIDS Society and 
Stanford databases, respectively (Simen 2007).
These rates ﬂ  uctuate greatly based on geographic region, 
which often reﬂ  ects access to medications. Recently pub-
lished resistance rates range from lows of 5.5%–7.4% in 
Africa, East and Southeast Asia, and Latin American to highs 
of 10.6%–11.4% in Europe and North America (Maglione 
et al 2007). While some have predicted rates of multidrug 
resistance decreasing in the coming years (Blower et al 2007), 
clinicians are still faced with trying to understand what is 
present today. In order to most appropriately perform this 
task, it cannot be emphasized enough that current (online 
sources) geographically appropriate information is required. 
Even in a country with relatively high rates of antiretroviral 
usage (USA), variance existed. Overall 11%–13% of samples 
tested demonstrated resistance to at least one class of drugs, 
but that even within this one country varied from 8%–13% 
(Ross et al 2007). The change in resistance rates over this 
study period, by class of drug, is noteworthy. While NRTI 
and PI rates remained relatively stable 3%–4% and 2% (no 
change), respectively, NNRTI rates rose from 2% to 7% 
(Ross et al 2007). This trend is mimicked by recent data 
comparing North America with Westerm Europe in that rates 
of NNRTI resistance rose from 4.4% to 8.7% and from 0% 
to 3.7%, respectively (Rahim et al 2007). Rates of resistance 
to the NRTI and PI classes, while increasing only slightly 
or stabilizing (Rahim et al 2007), will likely only remain as 
such with continued appropriate use of antiretroviral agents Therapeutics and Clinical Risk Management 2008:4(2) 294
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and early and repeated uses of resistance testing in those on 
or being considered for therapy.
Resistance patterns for the three components of Atripla™ 
have been deﬁ  ned by sequencing the RT-encoding gene of 
HIV clinical isolates that demonstrate reduced susceptibility 
to each drug in cell culture. These data come primarily from 
administration of the individual agents with the rate of resis-
tance for persons receiving Atripla™ detailed below. Resistant 
viral isolates have been found both in vitro and from patients 
receiving treatment (Atripla™ 2006). Primary mutations for 
tenofovir include K65R (the signature mutation), T69S, and a 
combination of three of the following: M41L, D67N, K70R, 
L210W, T215Y/F, or K219Q/E/N. Mutations observed in iso-
lates that show reduced susceptibility to emtricitabine include 
M184V/I (signature mutation), and K65R (when selected by 
other NRTIs). Lastly, mutations found to be associated with 
efavirenz resistance are K103N (signature mutation), A98G, 
L100I, K101E/P, V106A, Y181X, Y188X, G190X, P225H, 
F227L, or M230L (Atripla™ 2006). In general, tenofovir-resis-
tant isolates (K65R) tend be less sensitive to emtricitabine, 
but are hypersusceptible to efavirenz (Atripla™ 2006).
Two recent studies reported on the development of drug 
resistance when these agents are administered in combina-
tion. Though neither of these studies used the actual Atripla™ 
formulation, the three elements were used as a regimen. 
In one (GS-99-934), resistance was observed in 9 of 244 
patients (3.7%) (Gallant et al 2006). Of the study participants 
who developed resistance, all contained NNRTI-associated 
mutations and two had the M184V mutation (emtricitabine 
signature mutation). It was interesting that no resistance was 
associated with the K65R mutation in this study. Furthermore, 
after 96 weeks, study participants had less overall resistance 
compared to participants on a combination of two other NRTI 
drugs (lamivudine and zidovudine) plus efavirenz (McColl 
et al 2006). No participants receiving the tenofovir containing 
regimen developed the K65R mutation (signature mutation 
for tenofovir resistance). In the second study (ACTG 5142), 
33% (n = 11/33) and 48% (n = 16/33) of those virologically 
failing developed resistance to a NRTI or NNRTI component, 
respectively (Riddler et al 2006). Of the NRTI mutations, 
8/11 were found to have M184V and 3/11 developed K65R. 
The NNRTI signature mutation of K103N was seen in 9/16. 
Clinicians using resistance testing in persons receiving these 
agents should be vigilant for these mutations.
Pharmacokinetics
One Atripla™ tablet is bioequivalent to efavirenz 600 mg, 
emtricitabine 200 mg, and tenfovir diprovoxil fumarate 300 mg
after single-dose administration to fasting healthy volun-
teers (Mathias 2006). The pharmacokinetic properties of the 
individual agents found in Atripla™ are discussed below.
Emtricitabine
Following oral administration, emtricitabine is rapidly 
absorbed with peak plasma concentrations occurring at 1–2 
hours post-dose. Following multiple dose oral administration 
to 20 HIV-infected subjects, the steady-state plasma dosing 
interval was 1.8 ± 0.7 µg/mL (mean ± SD) and the AUC over 
a 24-hour dosing interval was 10.0 ± 3.0 µg/h/mL. Mean 
absolute bioavailability is 93%. Emtricitabine has low protein 
binding ( 4%). Following oral administration, approximately 
86% of the dose is excreted in the urine (by a combination of 
glomerular ﬁ  ltration and active tubular secretion), with 13% 
of the dose excreted as metabolites. The inactive metabolites 
of emtricitabine include 3’-sulfoxide diastereomers and their 
glucuronic acid conjugate (Atripla™ 2006).
Tenofovir diprovoxil fumarate
After single dose oral administration of 300 mg tenofovir 
DF to HIV-infected subjects, maximum serum concentrations 
were achieved at 1.0 ± 0.4 hours (mean ± SD) and Cmax and 
AUC values were 296 ± 90 mg/mL and 2287 ± 685 mg/h/mL, 
respectively. The oral bioavailability of tenofovir from 
tenofovir DF in fasted patients is approximately 25%. Protein 
binding is low ( 0.7%). Approximately 70%–80% of the 
intravenous dose of tenofovir is recovered unchanged in 
the urine. Tenofovir is eliminated renally by a combination 
of glomerular filtration and active tubular secretion 
(Atripla™ 2006).
Efavirenz
Following 600 mg once-daily administration, Cmax at steady 
state was 12.9 ± 3.7 µM (mean ± SD), Cmin was 5.6 ± 3.2 µM 
and AUC was 184 ± 73 µM/h. Efavirenz is highly protein 
bound ( 99%) to human plasma proteins, predominantly 
albumin. Efavirenz is metabolized primarily by CYP2B6 and 
to a lesser extent, CYP3A4 and it has been demonstrated that 
efavirenz induces predominantly CYP3A4. Fourteen to 24% 
of efavirenz dose is excreted renally primarily as metabolites 
and 16%–61% of the dose is excreted in the feces as parent 
drug (Atripla™ 2006).
Food effects
As no formal drug-food interaction studies have been 
conducted and also due to increased drug exposure to 
efavirenz and tenofovir when taken with a high fat meal, it is Therapeutics and Clinical Risk Management 2008:4(2) 295
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recommended that the dose of Atripla™ be taken once daily 
on an empty stomach (Atripla™ 2006).
Special populations
Sex
The pharmacokinetics of emtricitabine and tenofovir are 
similar between males and females. The results of stud-
ies examining sex differences in the pharmacokinetics of 
efavirenz are not fully conclusive. Three investigations 
have shown no inﬂ  uence of sex on the concentrations of 
efavirenz, whereas other studies have demonstrated mean 
efavirenz concentrations or a decrease in clearance in females 
compared with males (Barrett et al 2002; Csajka et al 2003; 
Lamba et al 2003; Kappelhoff et al 2005). At this time, 
there are no recommendations to alter doses based on sex 
(Atripla™ 2006).
Race
Ethnicity does not appear to alter the pharmacokinetics of 
emtricitabine (Emtriva® 2006). Data regarding the effects of 
race or ethnicity on tenofovir pharmacokinetics are limited at 
this time (Viread® 2007). There are ethnic-related differences 
in the pharmacokinetics of efavirenz. These may be related to 
genetic diversity found in the primarily metabolizing enzyme 
of efavirenz, CYP450-2B6 (see section below), but ongo-
ing research will hopefully provide deﬁ  nitive explanations 
(Gatanaga et al 2007). Nonetheless, higher plasma concen-
trations and lower clearance values for efavirenz have been 
observed in Hispanics and African ethnic groups as compared 
to non-Hispanic whites (Csajka et al 2003; Pﬁ  ster et al 2003). 
Currently, there are no recommendations to alter dose based 
on race (Atripla™ 2006), but enhanced vigilance in these 
populations for efavirenz adverse effects is warranted.
Renal impairment
The pharmacokinetics of emtricitabine and tenofovir (given 
as tenofovir) are altered in renal impairment. Emtricitabine 
AUC values increased 2.1-fold [11.8 h*µg/mL (± 2.9) to 
25.1 h*µg/mL (±5.7)] in patients with a creatinine clearance 
of  80 mL/min compared to those with creatinine clearance 
of 30–49 mL/min. (Emtriva® 2006) Tenofovir’s AUC values 
mimicked this as well, increasing 2.75-fold [2184 h*µg/mL 
(±257) to 6008 h*µg/mL (± 2504)] given similar changes in 
renal function (Viread® 2007). As efavirenz does not require 
dose adjustment based on renal dysfunction, Atripla™ should 
not be administered to patients with a creatinine clearance of 
 50 mL/min (Atripla™ 2006). If these agents are to be admin-
istered, separate dosage forms would need to be employed.
Hepatic impairment
The pharmacokinetics of tenofovir is not substantially altered 
by the presence of hepatic impairment (Viread® 2007). 
Because it is not extensively metabolized and is primarily 
renally eliminated, emtricitabine disposition would not be 
expected to be signiﬁ  cantly altered with hepatic impairment 
(although to date this has not been well studied) (Emtriva® 
2006). Given efavirenz’s extensive hepatic metabolism, 
the manufacturer warns against using Atripla™ in patients 
with hepatic liver functions that are greater than 5 times 
upper limit of normal (Atripla™ 2006). This must be taken 
in concert with current treatment guidelines that recognize 
that though the risk for adverse effects is increased in those 
with hepatic impairment, that efavirenz instead should 
be used “with caution” (Bartlett and Lane 2007).
Genetic inﬂ  uences 
on the pharmacokinetics
Host genetic polymorphisms in drug metabolizing enzymes 
may also inﬂ  uence drug concentrations, drug clearance 
and/or drug efﬁ  cacy (Gatanaga et al 2007). Efavirenz is 
metabolized primarily by CYP2B6 (Ribaudo et al 2006). 
The gene that encodes for CYP2B6 is highly polymorphic 
and has numerous single nucleotide polymorphisms (SNP) 
and associated haplotypes (Haas et al 2004). One important 
2B6 polymorphism is the 2B6 G516T SNP. One study has 
demonstrated that the 516TT genotype of CYP2B6 was 
associated with higher plasma efavirenz concentrations (up 
to 3 times higher AUC in the TT variant) and predicted cen-
tral nervous system side effects at week 1 of therapy (Haas 
et al 2004). However, tolerance to the CNS adverse effects 
developed after the ﬁ  rst week, despite maintained higher 
efavirenz drug exposure (Haas et al 2004). In addition, ethnic 
differences in the frequency of the polymorphism were found. 
The frequency of the 516TT variant was higher in African 
Americans (20%) and European Americans (3%).
Other investigators have demonstrated that the G516T 
SNP also dictates efavirenz plasma half-life after discontinu-
ation of efavirenz therapy. Essentially those with the faster 
metabolizing capability (GG) are able to ‘metabolize’ their 
side effects away as compared to those with the TT alleles 
(Ribaudo et al 2006). This ﬁ  nding led authors to speculate 
that the mutation may alter the risk of the development of 
drug resistance in patients discontinuing efavirenz contain-
ing therapy (Ribaudo et al 2006). Others have demonstrated 
that response to efavirenz treatment is due to a complex 
phenotype that is inﬂ  uenced by multiple genes, of which 
the G516T polymorphism is only one component of the Therapeutics and Clinical Risk Management 2008:4(2) 296
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haplotype (Motsinger et al 2006). Additional studies are 
needed to clarify the genetic inﬂ  uences on efavirenz phar-
macokinetics in order to improve the ability to individualize 
therapy and provide enhanced treatment strategies for HIV 
infected persons (Gatanaga et al 2007).
Drug interactions
There are many pertinent drug interactions associated 
with the individual drug components of Atripla™. Brieﬂ  y, 
Atripla™ should not be co-administered with the antifungal 
drug voriconazole because efavirenz signiﬁ  cantly decreases 
plasma concentrations of voriconazole (Atripla™ 2006). It 
is also not recommended that benzodiazepines (midazolam 
and triazolam) or ergot derivatives be used concurrently with 
Atripla™ due to the potential for prolonged or increased seda-
tion (benzodiazepines) or peripheral vasospasms/ischemia of 
peripheral tissues (ergot derivatives). This interaction involves 
efavirenz’s inhibitory effect on CYP540-3A4 (Atripla™ 2006). 
A recommended website to use for checking antiretroviral’s 
drug interactions is www.hiv-druginteractions.org. This 
comprehensive site provides timely and referenced material 
related to the multitude of complicated interactions.
Adverse events and toxicity
There has been only one publication to date regarding use of 
the actual approved product (Mathias et al 2007). In this study, 
a single dose of Atripla™ was compared to a single dose of the 
individual medications (efavirenz + emtricitabine + tenofovir 
DF) in 48 fasting, non-HIV infected volunteers for pharma-
cokinetic purposes (Mathias et al 2007). Mild and transient 
headaches and dizziness were the most common adverse 
event, occurring in 24% of the volunteers receiving Atripla™ 
compared with 29% of the volunteers receiving the agents as 
individual agents (not signiﬁ  cantly different). It is noteworthy, 
however that there were two serious adverse events in this 
trial. both were spontaneous abortions in the ﬁ  rst trimester of 
pregnancy (this is described in greater detail below).
To date, there have been no large controlled clinical trials 
to evaluate the safety and tolerability of Atripla™ administered 
as approved and what is found in the package insert provides 
extrapolated information from previous studies (Atripla™ 
2006). The following are based on adverse event data col-
lected from studies (GS-99-934 and GS-99-903) using all 
three agents either as two (Sustiva® + Truvada®) or three 
(Sustiva® + Emtriva® + Viread®) individual agents (Gallant 
et al 2006; Arribas et al 2007a). Even within these studies, 
as the combination product (Truvada®) became available, 
adverse events and efﬁ  cacy were not reported by speciﬁ  c 
elements, thus the generalization is made that these would 
not be different were these given together or separately. 
Additionally, another large dataset of adverse events can be 
cautiously extrapolated from ACTG 5142 in that tenofovir + 
efavirenz were primarily used in the NNRTI + 2 NRTI arm of 
this study, although lamivudine (Epivir®, Glaxo-SmithKline, 
Research Triangle Park, NC, USA) was used as the third agent 
and not emtricitabine (Riddler et al 2006).
In study GS-99-934, 63% (n = 163/257) and 56% 
(n = 142/254) of the efavirenz + emtricitabine + tenofovir 
group were found to have clinical and laboratory adverse 
events, respectively (Gallant et al 2006). The most com-
mon clinical events (occurring in  5% of patients) were 
dizziness, nausea, diarrhea, fatigue, headache and rash in 
this report. In the ACTG conducted study, 18% and 32% 
of participants were found to have Grade 3 or 4 clinical or 
laboratory adverse events, respectively (Riddler et al 2006). 
The clinical events reported here were not delineated by study 
arm unfortunately. Table 1 displays the primary laboratory 
abnormalities from these reports. Importantly, both studies 
had  10% participants discontinue due to intolerance/tox-
icity. System speciﬁ  c information on adverse events can be 
found in sections below.
Pregnancy
Women who are pregnant or planning to become pregnant 
should not take Atripla®. Women of child-bearing potential 
should be advised to use appropriate methods of birth control. 
Efavirenz has a well-established pregnancy contraindication 
and carries this into Atripla™ as noted by receiving a “D” 
pregnancy category rating (Atripla™ 2006). Documentation 
of pregnancy status should be veriﬁ  ed prior to initiating 
ATRIPLA in women with childbearing potential.
Efavirenz
Neurological/psychiatric
Nervous system adverse events usually appeared during 
the ﬁ  rst or second day of drug administration and generally 
resolved within 2–4 weeks of treatment (Atripla™ 2006). These 
events appear to be intensiﬁ  ed with the use of alcohol or recre-
ational drugs. This time-period, when the patient is at greatest 
risk for neurological adverse events, may present the greatest 
risk for poor adherence (see Adherence section below).
Skin rash
Mild to moderate maculopapular skin rashes occurring within 
the ﬁ  rst two weeks of therapy can be seen in up to 26% with 
severe reactions (Stevens-Johnson syndrome) occurring in Therapeutics and Clinical Risk Management 2008:4(2) 297
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less than 1% of patients treated with efavirenz (Atripla™ 
2006). The typical skin reactions generally tend to be mild, 
responsive to antihistamine and/or oral corticosteroid therapy 
and usually resolve within 30 days.
Hepatic
As noted in the pharmacokinetic section, efavirenz is 
primarily eliminated by the liver (Atripla™ 2006). Cases of 
lactic acidosis and severe hepatomegaly have been reported 
and may be more likely to occur in those with pre-existing 
hepatic disease, concomitant administration of NRTI or other 
hepatically metabolized agents.
Tenofovir/emtricitabine
Adverse reactions that occurred in at least 5% of patients 
receiving tenofovir/emtricitabine include: anxiety, arthralgia, 
increased cough, dyspepsia, fever, myalgia, pain, abdominal 
pain, back pain, paresthesia, peripheral neuropathy, pneumo-
nia, rhinitis, rash, urticaria, allergic reactions.
Patients receiving emtricitabine have reported a higher 
incidence of skin discoloration especially on their palms 
and soles of their feet. This change in skin pigmentation is 
usually asympatomatic, but may not resolve or do so slowly 
with discontinuation (Emtriva® 2006).
A decrease in bone mineral density (BMD) has been 
reported in patients receiving tenofovir. After 144-weeks 
of administration, protocol deﬁ  ned decreases in BMD was 
seen in 28% of the tenofovir DF group vs 21% of the control 
group (GS-99-903) (Gallant et al 2006). A statistically greater 
decrease in BMD of the lumbar spine and hip occurred in 
the tenofovir + efavirenz + lamivudine arm (p = 0.001 and 
p   0.06, respectively) (Gallant 2006). From a clinically 
relevant standpoint, these changes occurred by week 24–48 
and stabilized by week 144 and all fractures on this arm of 
the study were related to trauma.
Lactic acidosis and severe hepatomegaly with steatosis 
have been reported with nucleoside analogs, such as emtric-
itabine and tenofovir albeit to an extent much less than seen 
with other drugs in this class (Abramowicz 2006a). Nonethe-
less, caution is warranted is used in patients with known risk 
factors for liver disesase. Though Atripla™ is not indicated 
for the treatment of chronic hepatitis B infection (HBV), 
both emtricitabine and tenofovir exhibit some activity against 
HBV (Emtriva® 2006; Viread® 2006). Importantly, ‘ﬂ  ares’ 
or exacerbations of HBV have been reported in patients 
upon discontinuation of emtricitabine and tenofovir (Bartlett 
and Lane 2007). Recent treatment guidelines recommend 
that in co-infected patients (HBV – HIV) fully suppressive 
antiretroviral regimens contain elements effective against 
HBV (tenofovir, emtricitabine or lamivudine) (Bartlett and 
Lane 2007).
Both tenofovir and emtricitabine undergo renal elimination, 
but only tenofovir (perhaps as a result of its active tubular 
efflux) has been associated with post-marketing reports 
Table 1 Adverse events occurring in  1% of persons on Atripla™ containing elements (Gallant et al 2006; Riddler et al 2006)
GS-99-934 (through 48 weeks) 
(used all three elements of 
Atripla®)
GS-99-903 (though 144 
weeks) (lamivudine in place of 
emtricitabine)
ACTG 5142 (through 96 
weeks) (lamivudine in place of 
emtricitabine, n = 85)
N = 257 N = 296 N = 250 (all NRTI combinations)
Fasting cholesterol  240 mg/mL 15% NR NR
Creatine kinase M:  990 U/L and 
F:  845 U/L
7% 12% NR
Serum amylase  175 U/L 7% 9% NR
AST M:  180 U/L and F:  170 U/L 3% 5% 4% ( 5x ULN)
ALT M:  215 U/L and F:  170 U/L 2% 4% 3% ( 5x ULN)
Alkaline phosphatase  550 U/L 1% NR NR
Hemoglobin  8.0 mg/dL 0% NR NR
Hyperglycemia  250 mg/dL 1% NR NR
Hematuria  75 RBC/HPF 2% 6% NR
Neutrophils 3%( 1000 mg/mm3) 3% 5%( 750 mg/mm3)
Fasting triglyceride  750 mg/dL 4% 3% 3%
Abbreviations: ALT, alanine aminotransferase;   AST, aspartate aminotransferase; RBC/HPF, red blood cells per high power ﬁ  eld; NRTI, nucleoside reverse transcriptase 
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of renal toxicity (nephrogenic diabetes insipidus, Fanconi 
Syndrome, acute renal failure) and the most recent treatment 
guidelines list nephrotoxicity to potentially occur with its use 
(Karras et al 2003; Rollot et al 2003; Peyriere et al 2004; Ray 
et al 2006; Viread® 2006; Bartlett and Lane 2007). Despite 
a multitude of case reports appearing in the literature, it is 
important to reﬂ  ect on the scientiﬁ  c rigor of case reports or 
series as compared to more formal comparisons using larger 
datasets – both prospective and retrospective, in treatment 
naïve and experienced patients, patients with normal and 
mild renal dysfunction, patients with and without diabetes 
mellitus, comparing women to men, which have assessed the 
renal toxicity of this agent (Izzedine et al 2004; 2005; Enejosa 
et al 2006; Gallant et al 2006; Staszewski et al 2006). Using 
this approach, the incidence of tenofovir-induced renal toxic-
ity, based on current data is seemingly occurring at the same 
rate as the comparator agent(s) in each instance. Some have 
suggested assessing for an inﬂ  uence of tenofovir on renal 
function when a combination of abnormal plasma glucose and 
hypophosphoremia are present (Izzedine et al 2004).
Economic implications of Atripla™
When the combination product Atripla™ (efavirenz/emtric-
itabine/tenofovir) was released, it was slightly more expensive 
($1,381) than purchasing the three components individually 
($1,363) based on wholesale pricing (Abramowicz 2006a). 
If however, the patient had a copay in addition to the aver-
age wholesale price, Atripla™ would then cost the individual 
less (three co-pays vs one co-pay). From 2006 to 2007, the 
costs for all of these medications have increased. Based on 
current wholesale prices, Atripla™ is cheaper ($1,465 vs 
$1,479 per 30 days’ supply) than if the three components 
are purchased individually (Fleming 2007). If the combination 
product, Truvada® (emtricitabine/tenofovir) is purchased and 
taken with efavirenz which provides the same combinations 
of medicines the cost is identical to purchasing Atripla™. 
Unless there are co-pays involved, there is no cost advantage 
of using Atripla™ over Truvada® plus efavirenz.
Atripla™ efﬁ  cacy and place 
in therapy
Atripla™ is indicated for the treatment of HIV-1 infection in 
treatment naïve adults (Atripla™ 2006). Atripla™ is effective 
against HIV-1 infection alone, as a complete regimen, or in 
combination with other antiretroviral agents. All three antiret-
roviral agents have proven to be effective in the treatment of 
HIV-1 infection when combined appropriately (Abramowicz 
2006b; Bartlett and Lane 2006; Hammer et al 2006; Bartlett 
and Lane 2007). There are multiple regimens for the initial 
treatment of HIV-1 infection in adults and many factors play 
a role in the selection of that initial regimen. The INITIO 
study compared the efﬁ  cacy of two NRTI in combination 
with either a NNRTI, a PI or both. INITIO revealed that 
patients on the combination containing the NNRTI had 
achieved a higher rate of viral suppression with increased 
CD4 counts after 3 years of therapy when compared to the 
other two regimens (Frampton and Croom 2006). In part 
due to the INITIO study, many current HIV-1 initial treat-
ment guidelines recommend the initial treatment of HIV-1 
infection contain the non-nucleoside, efavirenz, combined 
with two NRTI (zidovudine or tenofovir plus lamivudine or 
emtricitabine) (Pozniak et al 2006; Bartlett and Lane 2007) 
GS-99-934 compared the elements contained in Atripla™ 
(drugs were individually administered and not available as 
a ﬁ  xed-dose combination) versus ﬁ  xed-dose Combivir® (zid-
ovudine and lamivudine ﬁ  xed dose twice daily) plus efavirenz 
in antiretroviral naïve patients. (Pozniak et al 2006). At week 
48, 84% of subjects on the agents in Atripla™ had achieved a 
HIV RNA less than 400 c/mL compared to 73% of patients 
on the combivir/efavirenz regimen (p   0.05). At week 96, 
75% of subjects on the elements of Atripla™ had reached a 
HIV RNA less than 400 c/mL with 67% of subjects reaching 
a HIV RNA less than 50 c/mL compared to 62% of subjects 
on the Combivir/efavirenz regimen had reached a HIV RNA 
less than 400 c/mL with 61% reaching a HIV RNA less 
than 50 c/mL (statistically signiﬁ  cant for the  400 measure 
only, p = 0.004). Thus, a consistent virologic response 
advantage to using the elements contained in Atripla™ was 
seen. Subjects on the elements of Atripla™ had an increase 
in their CD4 count of 270 from baseline, while subjects on 
the other regimen had a CD4 count increase of 237 from 
baseline at week 96 (p = 0.036). Ten of the subjects on the 
elements of Atripla™ developed resistance during the study 
while twenty patients on the combivir/efavirenz regimen 
developed resistance, primarily manifesting as resistance 
to lamivudine or emtricitabine (M184V) (p = 0.036). No 
patients’ virus, when undergoing resistance testing after 
meeting protocol deﬁ  nition of virologic failure (consecutive 
viral loads of  400 copies/mL after previously respond-
ing) to the elements of Atripla™ developed a K65R muta-
tion (signature resistance mutation for tenofovir) (McColl 
et al 2006; Pozniak et al 2006) GS-99-934 concluded that 
those subjects on the elements of Atripla™ had a signiﬁ  -
cantly greater virologic suppression to HIV RNA less than 
400 c/mL and a greater increase in CD4 cell count from 
baseline (Pozniak et al 2006).Therapeutics and Clinical Risk Management 2008:4(2) 299
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GS-99-934 was the largest study conducted on the use of 
the elements of Atripla™ in treatment naïve subjects. Since 
this regimen worked well on treatment naïve subjects, ques-
tions were raised to its efﬁ  cacy on treatment-experienced 
subjects. To evaluate the efﬁ  cacy of Atripla™ in experienced 
patients, the COMET study was undertaken. COMET com-
pared the effect of switching HIV-1 antiretroviral experi-
enced subjects, who were stable on efavirenz, lamivudine, 
and zidovudine (not necessarily receiving Combivir®), to 
Atripla™. Those subjects that were switched to Atripla™ 
maintained viral suppression to less than 400 c/mL at week 
24 and the proportion of patients with viral suppression to 
less than 50 copies increased signiﬁ  cantly from 59% prior 
to the switch to 76% 24 weeks after the switch (Frampton 
and Croom 2006). These data may not necessarily support 
a difference in antiviral activity between the two regimens, 
but instead lend credence to long-standing principles of 
improved efﬁ  cacy of medications through improvements in 
dosing and adherence.
One arm (n = 299) of the GS-99-903 study that was 
reported out to 144 weeks used 2 of the 3 elements of Atri-
pla™, with the modiﬁ  cation being lamivudine used in the 
place of emtricitabine (Gallant et al 2006). Brieﬂ  y, the data 
from this study provides additional support that the combina-
tion of efavirenz with tenofovir (and in this instance lami-
vudine) represents an effective antiretroviral regimen with 
over 70% of participants achieving and maintaining virologic 
suppression (viral load  400 copies/mL) for this prolonged 
period. Further, immunologic response was mean increase 
in CD4 cells of 263 cells/µL and while neither immunologic 
or virologic responses were statistically different than the 
comparator arm, this demonstrates the staying power of these 
two elements of Atripla™.
Lastly, ACTG 5142 reported success using NNRTI based 
therapy in comparison to a ‘boosted’ PI anchored by lopi-
navir/ritonavir (Kaletra®, Abbott Laboratories, Abbott Park, 
ILL, USA) (Riddler et al 2006). As emtricitabine was not 
allowed as part of the NRTI backbone but instead lamivudine 
was used, a cautious and brief summary of this study is 
included. In this conference report, the NNRTI based regimen 
was superior to the PI based regimen as it pertains to time to 
virologic failure (p = 0.006), and a statistically signiﬁ  cant 
difference was noted in percentage of participants with viral 
loads of  400 (p = 0.41) and  50 copies/mL (p = 0.003) 
when comparing the NNRTI based regimen to the PI based 
one (93% vs 86% and 89% vs 77%, respectively). Cau-
tion is recommended in considering this information as 
CD4 recovery was superior with the PI containing regimen 
(285 vs 241 cells/µL, p = 0.01) and may warrant greater 
consideration, dependent on the patient’s needs.
Adherence
Lack of adherence to a medical regimen is a persistent prob-
lem for health care providers. Non-adherence for medications 
can range from 15% to 93%, with the average rate being 
50% non-adherence for chronic health conditions (Haynes 
et al 1979; McDonald et al 2002; Rueda et al 2007). In HIV 
patients participating in an antiretroviral adherence study, 
only about 30% (n = 24/81) of patients showed acceptable 
( 95% measured by MEMS caps) adherence to their thera-
peutic regimen (Paterson et al 2000). Providers strive to 
enhance adherence in HIV patients and view a 95% adher-
ence rate to the treatment regimen as capable of producing 
the greatest treatment effect and diminishing the likelihood 
of resistant strains from developing (Vervoort et al 2006).
In individuals infected with HIV, lack of adherence to 
the medication regimen not only can increase the likelihood 
of negative outcomes for the individual patient, but can 
also lead to development and spread of multi-drug-resistant 
strains of the virus (Murri et al 2004). Failure to adhere to 
a medication regimen in HIV-infected individuals can thus 
result in disproportionate societal costs through transmission 
of drug-resistant strains to others.
Complex treatment regimens are commonly associated 
with poor compliance, and simpliﬁ  cation of the regimen 
is among the most common recommendations to enhance 
adherence (van Dulmen et al 2007). Complexity in treatment 
has many components, including the number of pills that the 
patient must take, the number of daily doses and their timing, 
the requirement to take medications with/without meals, and 
the degree to which the regimen affects the patient’s activities 
of daily living (van Dulmen et al 2007). Many HAART 
therapies are highly complex. Technical solutions, including 
automated reminders to take medications (eg, medication 
dispensers, electronic alerts), can improve adherence, but 
simpliﬁ  cation is probably more effective overall.
Complexity in the medication regimen has ripple effects 
throughout the healthcare team. Clear instructions from pro-
viders are associated with improved adherence, but the ability 
of providers to give clear instructions about the medication 
regimen is compromised when the regimen is complex. 
Patients may experience lowered self-efﬁ  cacy about their 
ability to adhere to a complex regimen over their lifetimes, and 
this can reduce their willingness to adhere to the regimen.
Because Atripla™ combines three different antiretroviral 
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should be better than with more complex HAART. Atripla™ 
is taken once a day, and patients are encouraged to take it at 
night to minimize side effects, on an empty stomach. Theo-
retically, adherence rates to Atripla™ should be better than 
for the three individual antiretroviral therapies that make up 
Atripla™. Unfortunately, there are no data that speak to this 
hypothesis as current studies comparing the two regimens 
mandated equivalent adherence in order for subjects to 
remain on study.
A simpler regimen should lead to clearer instructions 
from providers about how to take the medication. Because 
Atripla™ should be taken before bed, the regimen should 
interfere less with a patient’s activities of daily living and be 
easier to incorporate into a patient’s daily activity pattern.
Patient-focused perspectives
Multiple patient-related factors as associated with reduced 
adherence in HIV patients. These include low patient self-
efﬁ  cacy, psychological distress and depression, forgetfulness, 
and inadequate confidence in treatment effectiveness 
(Vervoort et al 2006). Patient self-efﬁ  cacy is the patient’s 
belief in their own ability to perform the needed behaviors to 
adhere to the regimen. Theoretically, HIV-infected patients 
who believe they can successfully carry out the instructions 
given by their providers are more likely to adhere to the treat-
ment program (Ammassari et al 2002). Because the recom-
mended regimen for Atripla™ is very simple, the self-efﬁ  cacy 
of patients to stay on the therapy should be enhanced.
Psychological distress, including depression, is a common 
correlate of many chronic disorders (Glaros and Glass 1993) 
and may also be associated with drug abuse. A few studies 
have suggested that treating depression enhances adherence 
to treatment in HIV patients (Sambamoorthi et al 2000; 
Turner et al 2003; Yun et al 2005; Chander et al 2006). 
Substituting Atripla™ for its individual components will not 
necessarily deal with psychological distress, and providers 
should remain alert to the presence of depression and other 
psychological disorders in their patients.
Forgetfulness can diminish adherence to treatment, and 
there are many sources of forgetfulness: AIDS-related demen-
tia may lead to forgetfulness. Forgetfulness may be a mecha-
nism to avoid having to deal with the everyday reality of HIV 
infection. Forgetfulness may occur because other demands on 
an individual’s time may take priority over medication taking. 
Forgetfulness should be a diminished issue with Atripla™. The 
so-called “Premack principle” states that an effective way to 
reinforce or increase the frequency of a less frequent behavior 
(medication-taking) is to make access to another, more favored 
or more frequent behavior contingent on engaging in the less 
frequent behavior. In other words, a patient can be counseled 
not to go to bed (a frequent, preferred behavior) until they have 
taken their medication (the less frequent behavior). Except 
for patients whose lives are chaotic, connecting ingestion of 
an Atripla™ tablet with sleep should improve adherence and 
diminish the likelihood that “forgetfulness” in all its forms will 
affect medication-taking. Data are needed to determine if this 
hypothesis can be supported.
Conclusion
This article has provided a concise review of the avail-
able data on Atripla™. This agent appears to be a plau-
sible regimen for most HIV infected populations without 
documented resistance to the agents contained within, with 
some exceptions (such as pregnancy potential, abnormal 
renal function) as noted above. Whether beginning in a naive 
patient or switching from other regimens for tolerability 
issues, Atripla™ represents a viable option. Its demonstrated 
advantages with respect to lipid and hematologic parameters 
and equivalent incidence of renal toxicity are tempered by 
the ﬁ  ndings of bone mineral density decreases, however. 
Combining multiple mechanisms of action in a single dos-
ing unit appears to improve efﬁ  cacy, increase the likelihood 
for adherence and maintain viral suppression compared to 
administering these agents independently. It is suggested 
other pharmaceutical companies assess the potential to 
replicate this for the remaining antiretrovirals.
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